Needham & Company Lowers Ests on Syntel (SYNT) Amid Special Dividend; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Syntel Announces Special Dividend
September 12, 2016 8:30 AM EDTTROY, Mich., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq: SYNT), a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced that its Board of Directors has declared a special cash dividend of $15 per share.Â
The special cash dividend, is payable on October 3, 2016, to shareholders of record at the close of business on September 22, 2016. Due to the size of the dividend, it is anticipated that the Companys common stock will begin trading ex-dividend (without the dividend), the first business day following the dividend... More
SyntheticMR AB: MAGiC Receives FDA Approval
September 9, 2016 4:18 AM EDTSTOCKHOLM--(BUSINESS WIRE)-- As previously communicated, SyntheticMRs partner GE Healthcare has announced that MAGiC is now 510(k) cleared by the U.S. FDA. MAGiC is a customized version of SyntheticMRs SyMRI® IMAGE software marketed by GE Healthcare under a license agreement.
FDA clearance of MAGiC is a very important step and a significant achievement by our partner GE Healthcare. The U.S. market alone is the largest MRI market globally. FDA clearance means that MAGiC now has regulatory approval and is available for sale on most major markets globally, says Stefan Tell, CEO of SyntheticMR.
MAGiC... More
